Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$30.97M+274.18%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian Webster
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 443
- Beta
- 0.62
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 4.50
Financials
KMTS has only 11 quarterly periods on file — the charts below show the full history available.
Revenue
$30.97M+274.2%Net Income
$-44.09MEBITDA
$-34.99MFree Cash Flow
$-40.63MEPS (diluted)
$-0.75Shares Outstanding (diluted)
58.57M+18.2%Operating Expenses
$55.16MCash & Debt
$198.91MReturn of Capital
$172.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $95.13M | $-131.61M | $-2.43 |
| 2025 | $59.81M | $-113.81M | $-5.13 |
| 2024 | $27.81M | $-94.12M | $-2.04 |
| 2023 | $7.63M | $-84.24M | $-1.75 |
Valuation
KMTShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (10)
- Newsseekingalpha.com·24d ago·Neutral
…n The Horizon Kestra Medical Technologies is transitioning into a high-growth, high-quality medtech platform with 60% YoY revenue growth and expanding gross margins. KMTS targets mid-70s gross margins within 2–3 years, driven by improved payer mix, scale, and supplier leverage, validating its unit economics story. Despite strong top-line momentum and raised FY27 guidance, profitability remains distant with a $44M net loss and $32M quarterly cash burn.
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcript
View source ↗ - Newszacks.com·25d ago·Negative
Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue Estimates Kestra Medical Technologies, Ltd. (KMTS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.61.
View source ↗ - Newsmarketbeat.com·25d ago·Neutral
Kestra Medical Technologies Q1 Earnings Call Highlights Kestra Medical Technologies NASDAQ: KMTS reported first-quarter fiscal 2027 revenue of $31 million, with President and Chief Executive Officer Brian Webster saying revenue rose 60% from a year earlier and advanced sequentially from the fourth quarter. The company raised its full-year revenue outlook to $141 million from a prior forecast of $137 million, representing expected growth of 48% over fiscal 2026.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results KIRKLAND, Wash., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the first quarter of fiscal year 2027, which ended July 31, 2026.
View source ↗ - Newsbenzinga.com·29d ago·Negative
Kestra Likely To Report Q1 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) will release its first earnings report after the closing bell on Monday, Sept.
View source ↗ - Newsglobenewswire.com·30d ago·Neutral
Kestra Names Daniel Finney Vice President of Research & Development KIRKLAND, Wash., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, announced today that Daniel Finney has been named Vice President of Research & Development and appointed to the company's executive leadership team.
View source ↗ - Newszacks.com·33d ago·Neutral
Analysts Estimate Kestra Medical Technologies, Ltd. (KMTS) to Report a Decline in Earnings: What to Look Out for Kestra Medical Technologies, Ltd. (KMTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Kestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14 KIRKLAND, Wash., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to report first quarter fiscal 2027 financial results after the market closes on Monday, September 14.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
…ra Appoints Curtis Kopf as Senior Vice President of Customer Experience KIRKLAND, Wash., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced the appointment of Curtis Kopf as Senior Vice President of Customer Experience. In this newly created role, Mr. Kopf will lead the patient experience from approval of a patient order through completion of therapy and device return, aligning the …
View source ↗
Earnings
Thu, Dec 10(in 2 months)
Consensus estimate $-0.61 per share
Typical surprise -13.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Sep 14$-0.75 vs $-0.62miss
- Tue, Jul 14$-0.67 vs $-0.59miss
- Tue, Mar 17$-0.61 vs $-0.60miss
- Thu, Dec 11$-0.62 vs $-0.59miss
- Thu, Sep 11$-0.46 vs $-0.66beat
- Tue, Jul 15$-2.21 vs $-0.53miss
Estimates and results for KMTS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KMTS officers and directors.
- Bought
- $1.1m
- Sold
- $9.0m
4 trades
45 trades
- Cohen Raymond Wsold
- Kwo Elizabethsold
- Schwartz Jeffrey Lawrencesold
- Hanley Conorsold
- Reilly Kevin Csold
- Ladone Mary Kaysold
- Webster Brian Danielsold
- Mahboob Vaseemsold
33 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in KMTS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.